Drug search by name

Rituximab and hyaluronidase human, recombinant Subcutaneous and Infections

Result of checking the interaction of drug Rituximab and hyaluronidase human, recombinant Subcutaneous and disease Infections for safety when used together.

Check result:

Rituximab and hyaluronidase human, recombinant Subcutaneous <> Infections

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Rituximab can cause serious, including fatal, bacterial, fungal, and new or reactivated viral infections during and following the completion of rituximab-based therapy. Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure). New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C. The manufacturer recommends discontinuing rituximab for serious infections and institute appropriate anti-infective therapy.

Rituximab and hyaluronidase human, recombinant Subcutaneous

Generic Name: hyaluronidase / rituximab

Brand Name: Rituxan Hycela

Synonyms: Hyaluronidase and rituximab, Rituximab and Hyaluronidase

What is Rituximab and hyaluronidase human, recombinant Subcutaneous?